All In Biotech

Drug Trial Radar · NCT06797869

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

142

Actual

Start

Jan 29, 2025

Primary completion

Jun 26, 2026

Study completion Aug 5, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.

Conditions

  • Diabetes Mellitus, Type 2
  • Diabetic Peripheral Neuropathy

Interventions

  • CagriSema (Cagrilintide B and Semaglutide I)Drug

    Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

  • Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Drug

    Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)Time frame: From baseline (week 0) to end of treatment (week 32)

Locations

55 sites in 7 countries. Site status is shown where the registry gives one.

  • eStudySite

    La Mesa, California

  • Linda Vista Health Care Ctr

    San Diego, California

  • My Preferred Research

    Miami, Florida

  • New Horizon Research Center

    Miami, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Foot & Ankle Center of Illinois

    Springfield, Illinois

  • Velocity Clinical Research Rockville

    Rockville, Maryland

  • Amicis Centers of Clinical Research

    St Louis, Missouri

  • DM Clinical

    Albuquerque, New Mexico

  • Southgate Medical Group, LLP

    West Seneca, New York

  • Piedmont Healthcare/Research

    Statesville, North Carolina

  • Lillestol Research LLC

    Fargo, North Dakota

  • Oregon Health & Science University

    Portland, Oregon

  • Clinical Res Collaborative

    Cumberland, Rhode Island

  • DM Clinical

    Houston, Texas

  • Radiance Clinical Research

    Lampasas, Texas

  • DM Clinical Research

    San Antonio, Texas

  • DM Clinical

    San Antonio, Texas

  • Velocity Clinical Research Portsmouth

    Suffolk, Virginia

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, Canada

  • Centricity Research Brampton Endocrinology

    Brampton, Ontario, Canada

  • Centricity Clinical Research Burlington

    Burlington, Ontario, Canada

  • Centricity Research Etobicoke Endocrinology

    Etobicoke, Ontario, Canada

  • Premier Clinical Trial Research Network (PCTRN)

    Hamilton, Ontario, Canada

  • Diabetes Heart Research Centre

    Toronto, Ontario, Canada

  • Ctr de Med Metab de Lanaudiere

    Terrebonne, Quebec, Canada

  • Aarhus Universitetshospital, Steno Diabetes Center Aarhus

    Aarhus N, Denmark

  • Steno Diabetes Center Nordjylland

    Gistrup, Denmark

  • Steno Diabetes Center Copenhagen

    Herlev, Denmark

  • Kolding Sygehus Karkirurgi

    Kolding, Denmark

  • Steno Diabetes Center Odense

    Odense C, Denmark

  • Les Hopitaux de Chartres-Hopital Louis Pasteur

    Le Coudray, France

  • Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu

    Le Creusot, France

  • Aphp-Hopital La Pitie Salpetriere

    Paris, France

  • Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque

    Pessac, France

  • Centre de Recherche Clinique Portes Du Sud

    Vénissieux, France

  • Haukeland Universitetssykehus

    Bergen, Norway

  • Sykehuset Innlandet HF Hamar

    Hamar, Norway

  • Oslo universitetssykehus, Ullevål

    Oslo, Norway

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.